Amneal Pharmaceuticals Inc. (NYSE:AMRX) went up by 8.80% from its latest closing price compared to the recent 1-year high of $7.45. The company’s stock price has collected 0.43% of gains in the last five trading sessions. Press Release reported 14 hours ago that Thinking about buying stock in Neurobo Pharmaceuticals, Xenetic Biosciences, Amneal Pharmaceuticals, PLx Pharma, or Orbital Energy Group?
Is It Worth Investing in Amneal Pharmaceuticals Inc. (NYSE :AMRX) Right Now?
Plus, the 36-month beta value for AMRX is at 1.22. Opinions of the stock are interesting as 4 analysts out of 8 who provided ratings for Amneal Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $6.92, which is $1.75 above the current price. AMRX currently public float of 116.81M and currently shorts hold a 3.65% ratio of that float. Today, the average trading volume of AMRX was 878.86K shares.
AMRX’s Market Performance
AMRX stocks went up by 0.43% for the week, with a monthly drop of -9.62% and a quarterly performance of -17.11%, while its annual performance rate touched 0.21%. The volatility ratio for the week stands at 6.74% while the volatility levels for the past 30 days are set at 4.55% for Amneal Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -4.97% for AMRX stocks with a simple moving average of -9.32% for the last 200 days.
Analysts’ Opinion of AMRX
Many brokerage firms have already submitted their reports for AMRX stocks, with RBC Capital Mkts repeating the rating for AMRX by listing it as a “Sector Perform.” The predicted price for AMRX in the upcoming period, according to RBC Capital Mkts is $5 based on the research report published on April 07th of the current year 2021.
Goldman, on the other hand, stated in their research note that they expect to see AMRX reach a price target of $6.50, previously predicting the price at $4. The rating they have provided for AMRX stocks is “Buy” according to the report published on March 08th, 2021.
Guggenheim gave a rating of “Buy” to AMRX, setting the target price at $5.50 in the report published on December 14th of the previous year.
AMRX Trading at -12.17% from the 50-Day Moving Average
After a stumble in the market that brought AMRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.87% of loss for the given period.
Volatility was left at 4.55%, however, over the last 30 days, the volatility rate increased by 6.74%, as shares sank -11.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.62% lower at present.
During the last 5 trading sessions, AMRX rose by +0.43%, which changed the moving average for the period of 200-days by +17.21% in comparison to the 20-day moving average, which settled at $4.92. In addition, Amneal Pharmaceuticals Inc. saw 2.84% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at AMRX starting from Todisco Joseph, who sale 36,330 shares at the price of $6.82 back on Mar 15. After this action, Todisco Joseph now owns 279,940 shares of Amneal Pharmaceuticals Inc., valued at $247,865 using the latest closing price.
Shah Nikita, the Executive Vice President of Amneal Pharmaceuticals Inc., sale 36,330 shares at $6.87 during a trade that took place back on Mar 15, which means that Shah Nikita is holding 211,921 shares at $249,489 based on the most recent closing price.
Stock Fundamentals for AMRX
Current profitability levels for the company are sitting at:
- +7.85 for the present operating margin
- +33.27 for the gross margin
The net margin for Amneal Pharmaceuticals Inc. stands at +4.57. The total capital return value is set at 4.87, while invested capital returns managed to touch 2.96. Equity return is now at value -5.60, with -0.40 for asset returns.
Based on Amneal Pharmaceuticals Inc. (AMRX), the company’s capital structure generated 971.12 points at debt to equity in total, while total debt to capital is 90.66. Total debt to assets is 73.52, with long-term debt to equity ratio resting at 952.10. Finally, the long-term debt to capital ratio is 88.89.
When we switch over and look at the enterprise to sales, we see a ratio of 1.67, with the company’s debt to enterprise value settled at 0.88. The receivables turnover for the company is 3.04 and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.29.